Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538547 | 0.85 | KMT2A (0.48) | POLBKMT2AKDM1ADAO | |
| SCHEMBL7072559 | 0.83 | KMT2A (0.47) | POLBKMT2AKDM1ADAO | |
| SCHEMBL7295324 | 0.81 | DAO (0.47) | POLBKMT2AKDM1ADAO | |
| SCHEMBL4672103 | 0.80 | OXER1 (0.52) | KMT2A | |
| SCHEMBL8520991 | 0.80 | HTR2A (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL26513551 | 0.79 | KDM1A (0.46) | POLBKMT2AKDM1A | |
| SCHEMBL6942314 | 0.79 | DAO (0.45) | POLBKMT2AKDM1ADAO | |
| SCHEMBL28223276 | 0.79 | OXER1 (0.53) | — | |
| SCHEMBL7246243 | 0.79 | NPC1 (0.49) | POLBKMT2AKDM1ADAO | |
| SCHEMBL1882418 | 0.79 | KMT2A (0.50) | POLBKMT2AKDM1ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-2816040-A1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-5360800-A | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | GLAXO GROUP LIMITED (GB) | 1994-11-01 | — | — | US | disclosed |
| EP-0306323-B1 | Lactam derivatives | GLAXO GROUP LTD (GB) | 1994-09-21 | — | — | EP | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | POLB 3067/4885KMT2A 4077/4885KDM1A 4753/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | POLB 4547/4885KMT2A 3415/4885KDM1A 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.